54 results about "Propofolum" patented technology

The invention relates to a deep learning method-based pharmacokinetics-pharmacodynamics and reinforcement learning-based propofol administration method and application thereof, a PKPD model is used for simulating the metabolic process of propofol in a human body, and a time dependency relationship and dynamics continuous information are extracted through LSTM and Neural OED; then a nonlinear relation between the propofol drug effect concentration and a clinically observed anesthesia depth index BIS is established through a Kan network, mapping between monitoring information and the anesthesia depth in an operation is rapidly established, a strategy is adjusted in time according to environment changes, and the method is suitable for processing non-standardized complex problems and has good application prospects. And the dosage and the administration scheme of the medicine are individually adjusted, so that the treatment effect is improved.

The invention discloses a substituted phenol compound as well as a preparation method and application thereof. According to the present invention, the propofol is subjected to structure optimization to obtain the compound having the structure represented by the formula (I), such that the safety is significantly improved, the anesthetic effect is excellent, various preparation forms can be conveniently prepared, the clinical application in various drug delivery forms can be easily achieved, the structure is novel, and the preparation method is simple. # imgabs0 #

The invention discloses a dexmedetomidine and propofol combined reagent and a combination method, and relates to the technical field of combined use of anesthetic drugs. According to the method, firstly, dexmedetomidine is subjected to intravenous pump injection within 5-15 minutes according to the dosage of 0.5-1.0 mu g / kg, propofol is given within 2 minutes after the dexmedetomidine is subjected to general anesthesia, and the dosage of the propofol can be reduced by 10%-50% compared with that of propofol which is independently used. Through pretreatment of dexmedetomidine, the anesthetic effect of propofol can be enhanced, adverse reactions such as blood pressure drop and respiratory depression can be effectively reduced, and anesthetic safety and controllability are improved. The combined reagent comprises independent containers for respectively loading the dexmedetomidine injection and the propofol emulsion, and can be packaged by adopting a double-cavity pre-filled injector, and sequential injection is realized through a controllable opening mechanism, so that unstable emulsification and titer change caused by physical mixing of medicines are avoided.

The invention discloses a children propofol anesthesia depth monitoring method based on permutation entropy and heart rate change, and belongs to the technical field of anesthesia depth monitoring, and the method comprises the following steps: extracting a children electroencephalogram, and carrying out preprocessing and spectral analysis on the children electroencephalogram to obtain permutation entropy; child heart rate data are extracted and processed to obtain the heart rate change degree; inputting the permutation entropy, the heart rate change degree and the age into the mixed prediction model to obtain a composite index, and indicating the narcotic depth of the propofol for the children. According to the children propofol anesthesia depth monitoring method based on the permutation entropy and the heart rate change, the mixed prediction model is constructed by combining the electroencephalogram permutation entropy, the heart rate change degree and the child patient age, and higher accuracy, real-time performance and reliability are shown in children propofol anesthesia depth monitoring; the anesthesia state change can be quickly responded, and the problem of misjudgment caused by age dependence and insufficient linear processing in the prior art is effectively solved.

The present invention relates to a continuous process for the preparation of a highly pure compound of formula III i.e. propofol, suitable for industrial or pharmaceutical use:

Pharmaceutical combinations of etomidate derivatives and propofol and pharmaceutical compositions thereof for use in anesthesia, sedation and / or hypnosis of animals or humans. The pharmaceutical composition of the etomidate derivative and the propofol or the pharmaceutical composition of the etomidate derivative and the propofol shows an excellent synergistic effect compared with independent administration and combined administration.

The present invention discloses a nanoprobe and portable detection device for detecting propofol in serum, relating to the field of biomedical detection technology. The nanoprobe comprises UCNPs and a diazonium salt, wherein the diazonium salt is formed by the reaction of p-aminobenzenesulfonic acid and sodium nitrite. The nanoprobe uses the diazonium salt as a propofol recognition unit, and the UCNPs as an energy donor. In the presence of propofol, the nanoprobe can cause luminescence quenching. The rapid and specific response between the diazonium salt and propofol enables rapid, sensitive, and visual detection of propofol.

This invention relates to the field of medical data processing technology, and discloses a method, system, device, and medium for calculating the synergistic control rate of drug infusion. The invention acquires the patient's real-time bispectral index (BSE) and determines its deviation from a preset target range. A control algorithm is then used to calculate the required total effect intensity adjustment. Based on a preset fixed ratio of propofol and remifentanil effect-site concentrations, the total effect intensity adjustment is allocated to the target effect-site concentrations of each drug. Finally, the target infusion rates of propofol and remifentanil are calculated backward using the Schnider and Minto models, respectively. This invention achieves synergistic closed-loop control of sedative and analgesic drugs based on a single BIS feedback, solving the clinical problem of unquantifiable analgesia control, ensuring a dynamic balance between sedation and analgesia, and incorporating a built-in safety verification mechanism. This significantly improves the accuracy, stability, and safety of anesthesia depth control, while reducing clinical workload.

An antibody for binding to propofol is provided. Also provided is an immunoassay for assaying propofol and a rapid, point-of-care immune-biosensor for propofol.

The utility model relates to the technical field of medicine pumping devices, and discloses a device for rapidly pumping a large amount of medicine at a time, which comprises a base, a plurality of medicine pumping devices and a plurality of medicine pumping devices, and is characterized in that the upper surface of the base is provided with a mounting frame; the medicine placing tray is arranged on the upper surface of the base, and medicine placing grooves are evenly distributed in the upper surface of the medicine placing tray; and the mounting grooves are formed in the two sides of the upper surface of the base, first hydraulic telescopic rods are mounted in the mounting grooves correspondingly, and a fixing frame is arranged above the base. A first hydraulic telescopic rod is started to drive a needle tube of an injector to be inserted into a propofol container, a second hydraulic telescopic rod is started to drive a mounting frame to move downwards, a motor is started to finally drive a medicine taking groove to move to the position below a push rod base, and the second hydraulic telescopic rod is started to drive the mounting frame to move upwards. And the push rod of the injector can be driven to move upwards to extract the liquid medicine in the propofol container, so that the time for extracting the propofol is saved, and meanwhile, the manpower of medical personnel is also saved.

This invention discloses an endothelin A receptor antagonist-albumin fusion protein and its application in preventing and treating hypotension during anesthesia induction. The fusion protein is formed by chemically coupling BQ-123 with human serum albumin (HSA). BQFu significantly enhances its antihypertensive effect by prolonging the half-life of BQ-123 and improving plasma stability. Experiments show that BQFu dose-dependently inhibits the decrease in mean arterial pressure (MAP) in a propofol-induced hypotension model, with a sustained and stable effect in the high-dose group (30 mpk), shortening the recovery time to 20.8 ± 10.5 min, while maintaining BQ-123 activity. This invention provides a long-acting and safe prevention and treatment strategy for hypotension during anesthesia induction.

The invention discloses application of GM1 in protection of nervous injury of developmental dogs caused by propofol anesthesia, and relates to the technical field of neuroprotective effect of GM1. The invention finds that the GM1 can relieve the hippocampus injury of a dog in the development period caused by propofol anesthesia and improve the cognitive function of the dog through anti-inflammatory, anti-pyroptosis and anti-oxidation effects, so that the neuroprotective effect is exerted; the GM1 can alleviate neuroinflammation, pyroptosis, oxidative stress and cognitive dysfunction of developmental dogs caused by propofol anesthesia by regulating a PI3K / Akt / NF-kappa B pathway and the expression of BDNF; 10 mg / kg of GM1 has a protective effect on nervous injury, caused by propofol anesthesia, of a developing-period dog, and has potential veterinary clinical application value.

The present application provides a propofol analogue, a preparation method thereof and application thereof in non-narcotic field. The propofol analogue has a structure as shown in general formula (G). The propofol analogue of the present application can greatly reduce or eliminate the affinity to GABA receptor, i.e. weaken or eliminate the narcotic property. It targets specific targets and shows effects in improving sleep, regulating blood pressure, relieving vomiting, resisting depression, protecting heart and brain, etc. (G).

The invention relates to a pharmaceutical composition for intraoperative brain protection in shoulder arthroscopy surgery. The pharmaceutical composition comprises midazolam, propofol, sufentanil, succinylcholine and atracurium besylate. According to the invention, rScO2 can be improved, the risk of cerebrovascular events can be reduced, but no obvious influence is generated on the circulation stability in the operation of a patient, the postoperative cognitive impairment and the like.

Abstract: A piperazine-substituted phenol derivative having the structure represented by formula (I) is provided. This compound not only has good salt-forming properties and excellent water solubility to meet pharmaceutical requirements, but also has a low minimum effective dose of anesthetics, rapid onset of action, and rapid recovery. This overcomes the drawbacks of prodrugs and lipid emulsion formulations of propofol and ciprofol, and is expected to be used in the preparation of drugs with sedative, hypnotic, and / or anesthetic effects and drugs for controlling status epilepticus. TIFF2025535407000076.tif41170

The invention relates to the technical field of biochemical detection, in particular to a pretreatment method of a propofol-containing sample, a propofol detection method and a kit. The pretreatment method of the propofol-containing sample comprises the following steps: providing the propofol-containing sample; the method comprises the following steps: adding porous polymer lipophilic magnetic beads into a sample, carrying out adsorption treatment, and then carrying out leaching treatment by using water and a methanol solution in sequence to obtain a propofol-magnetic bead compound; and eluting the propofol-magnetic bead compound by using an ammonia water methanol solution to obtain a sample to be detected. The pretreatment method provided by the invention is simple in process and low in cost, the to-be-detected sample containing propofol can be efficiently obtained, and the to-be-detected sample containing propofol can be subsequently used for high-sensitivity detection of propofol by an ion mobility spectrometry technology, so that the pretreatment method has a very good application prospect in the field of propofol detection.

An antibody for binding propofol is provided. Also provided is an immunoassay for assaying propofol and an immunobiosensor for rapid, point-of-care of propofol.

The invention relates to a transmission desorption electrospray low-pressure ion mobility spectrometry which comprises a transmission desorption electrospray ion source, an interface electrode and a low-pressure ion migration tube, the interface electrode is a metal sheet electrode with a through hole in the center, and the transmission desorption electrospray ion source is connected with the low-pressure ion migration tube through the interface electrode. The ion mobility spectrometry can realize efficient desorption spray ionization of substances difficult to volatilize in the detection process, the sample detection process is simplified, the working air pressure is lower than the atmospheric pressure, the detection sensitivity can be improved, furthermore, the ion mobility spectrometry is provided with a desolvation area and is combined with desolvation gas, the detection sensitivity can be further improved, and the detection accuracy is improved. High-sensitivity detection of anesthetic drugs such as propofol, etomidate, fentanyl and the like in blood can be realized through transmission-type desorption electrospray and low-pressure ion mobility spectrometry.

This invention relates to a propofol administration method based on deep learning-based pharmacokinetic-pharmacodynamic and reinforcement learning methods and its application. It uses a PKPD model to simulate the metabolic process of propofol in the human body, extracts time-dependent and kinetic continuous information through LSTM and Neural OED, and then establishes a nonlinear relationship between the effective concentration of propofol and the clinically observed anesthesia depth index (BIS) using a Kan network. This rapidly establishes a mapping between intraoperative monitoring information and anesthesia depth, allowing for timely adjustments to the strategy based on environmental changes. It is suitable for handling non-standardized and complex problems, enabling personalized adjustments to drug dosage and administration regimens, and improving therapeutic efficacy.

The invention discloses a propofol-metoprolol twin drug as well as a preparation method and application thereof, the propofol-metoprolol twin drug is formed by connecting propofol and metoprolol, and the propofol-metoprolol twin drug is named as WSW-E01-166-P. According to the present invention, the WSW-E01-166-P can achieve the deanesthesia effect, and has good drug stability; the compound has relatively high inhibition efficiency on ICa-L, and shows an anti-arrhythmia effect in a barium chloride induced ventricular arrhythmia rat model. The novel twin drug WSW-E01-166-P disclosed by the invention has relatively good performance in the aspects of IVAs resistance, pharmacokinetics, toxicology and the like, and is greatly helpful for later promotion of entering a phase I clinical research process.

The invention discloses a plasma metabolism biomarker combination for predicting and intervening propofol-induced respiratory depression, a detection method and application, and relates to the technical field of biological science. According to the method, non-target metabonomics detection is conducted on preoperative plasma of 298 subjects through UPLC-MS, 14-metabolite panels are obtained through machine learning supervised feature screening, a diagnosis model is established through verification of discovery and verification queues, and the prediction AUC of severe respiratory depression reaches 0.86-0.91 (discovery queue) and 0.86-0.91 (verification queue). Mouse in-vivo function verification proves that the key metabolite alpha-linolenic acid obviously improves the respiratory rate, the tidal volume and the minute ventilation volume under two administration paradigms of pretreatment and treatment of a mouse propofol-RD model, shortens the recovery time of righting reflex, has a good safety foundation, and has a good application prospect. Prompt can be converted into a foresight supplement or rapid treatment medication thought in a perioperative period, and a'prediction and intervention 'integrated clinical value is formed.

The invention discloses a nanoprobe for detecting propofol in serum and a portable detection device, and relates to the technical field of biomedical detection.The nanoprobe comprises UCNPs and diazonium salt, and the diazonium salt is formed by reaction of sulfanilic acid and sodium nitrite. According to the nanoprobe, the diazonium salt serves as a recognition unit of propofol, UCNPs serves as an energy donor, luminescence quenching can be caused in the presence of propofol, and rapid, sensitive and visual detection of propofol is achieved through rapid specific response between the diazonium salt and propofol.

The invention discloses a propofol drug delivery system and method based on appreciation electroencephalogram characteristics, a medium and a product, and relates to the field of intelligent medical systems, and the propofol drug delivery system comprises a signal collection module used for collecting original electroencephalogram signals; the signal processing module is used for mapping the real-time brain function state of the patient to a neural state space containing an appreciation related state and determining a neural state; the prediction calculation module is used for predicting a future evolution trajectory and a state transition probability of a neural state in a neural state space; the control decision module is used for generating a drug administration intervention strategy of propofol by taking the brain function state staying in the target appreciation area as a target; and the infusion execution module is used for adjusting the target control infusion pump according to the administration intervention strategy so as to guide and maintain the appreciation state. By implementing the application, the patient can be prevented from being in a poor sedative state as much as possible, and the operation prognosis effect is optimized.

The invention discloses an application of an alkyl acid compound in preparation of a medicine for regulating ethanol autonomous intake preference. The invention also discloses a pharmaceutical composition for adjusting the ethanol autonomous intake preference, and the pharmaceutical composition comprises the alkyl acid compound or the pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier and / or excipient. The application of the alkyl acid compound in preparing the medicine for adjusting the ethanol autonomous intake preference is provided for the first time, and animal experiments show that single injection of propofol into the tail vein of a mouse can continuously inhibit the ethanol autonomous intake preference of the mouse. The active ethanol intake absolute amount of mice and the relative ethanol intake proportion relative to the water intake amount can be obviously reduced, and the inhibition effect can last for at least 6 days.

The present invention relates to the field of pharmaceutical chemistry, and discloses flavonoid derivatives, preparation methods thereof, pharmaceutical compositions, and applications thereof. The general structural formula of the flavonoid derivatives is: wherein R2 and R'2 are independently selected from -H, -OH, or -OCH3; R3 and R'3 are independently selected from -H, -CH3, -OCH3, -CH(CH3)2, or -CH(CH2)2; R5 and R'5 are independently selected from -H, -CH3, -OCH3, -CH(CH3)2, or -CH(CH2)2; R6 and R'6 are independently selected from -H, -OH, or -OCH3. The flavonoid derivatives have enhanced lipid solubility, facilitate BBB penetration, increase drug concentration in the brain, maintain pharmacokinetic levels, effectively retain neuroprotective effects such as anti-oxidative stress, anti-inflammatory, and neuroregeneration, and introduce propofol into the flavonoid skeleton to enhance the anesthetic effect under the synergistic effect of the two, making them a potential new antidepressant drug.

The present application belongs to the technical field of chemical analysis and detection, and particularly relates to a method for improving the response speed of continuous monitoring of humidified propofol gas. The disclosed technical solution is characterized in that the sampling system and the gas transmission system are optimized in coordination. In the analysis mode, the flow meter (1) and the air suction pump are continuously operated to extract humidified propofol gas for sample analysis. In the cleaning mode, the flow meter (1) and the air suction pump are continuously operated, the flow meter (2) extracts clean air, the cleaning flow rate is controlled to be greater than the sample flow rate, the sample analysis is performed, and the heat tracing pipe and the buffer tank are cleaned. The monitoring is performed according to the analysis mode-cleaning mode-analysis mode switching, the rapid analysis and rapid cleaning are realized, the propofol adsorption and residue are reduced, the T90 and T10 of the system are significantly shortened, and the effects of continuous monitoring and rapid response are achieved.

Provided are a method and system for determining a population pharmacokinetic model of propofol and derivatives thereof. The method comprises determining a formula as a population pharmacokinetic model of a compound of formula (I) or propofol: wherein the formula of the pharmacokinetic parameters in the population pharmacokinetic model of the compound of formula (I) comprises: and the formula of the pharmacokinetic parameters in the population pharmacokinetic model of propofol comprises: formula (I).

The invention discloses a serum propofol separation and extraction method and a content determination method, and relates to the technical field of propofol detection.The serum propofol separation and extraction method comprises the steps that S1, protein in a serum sample is removed, and supernate without protein is obtained; s2, ultrasonically and uniformly mixing the supernate with an organic solvent, and centrifuging to obtain an organic phase containing propofol; the organic solvent is selected from one or more of methyl tert-butyl ether, dichloromethane and normal hexane. The method for determining the content of propofol comprises the following steps: adopting the serum propofol separation and extraction method; and mixing the organic phase with a molecular probe and an alkali solution, reacting, developing, and measuring an absorbance value. According to the scheme, propofol in serum can be separated and extracted, and the concentration of propofol can be accurately and rapidly detected.

The invention discloses a blood drug concentration test method and system based on dynamic thermal analysis and ion migration, comprising the following steps: for propofol blood drug mixed liquid, a gas phase state is formed by dynamic thermal analysis sampling; a carrier gas is introduced to drive the propofol blood drug mixture in the gas phase state to reach the ion migration functional area at a specific concentration and flow rate; the propofol blood drug mixture in the gas phase state in the ion migration functional area is ionized and ion migration is performed through a high-voltage electric field until the ions reach the electrode to measure the propofol blood drug concentration. The method solves the technical problem that when the gas phase monitoring of the corresponding blood drug concentration of propofol is performed in the prior art, there is a dynamic deviation between the propofol concentration of the exhaled gas and the actual propofol concentration of the plasma, which is easy to cause data inaccuracy and it is difficult to accurately and timely adjust the dosage and rate of propofol infusion.

This invention discloses a method for constructing a light anesthesia lozenge administration animal model, belonging to the field of biotechnology. The method involves administering propofol to animals, and after the righting reflex disappears, administering a lozenge to obtain a light anesthesia lozenge administration animal model. This method has good reproducibility, the experimental animals exhibit good tolerance, and it accurately simulates the clinical lozenge administration process, solving the key problem of discrepancies between the gavage administration route and clinical practice in traditional lozenge animal experiments.